Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
PE Firm Ampersand Capital Partners Acquires Purna Pharmaceuticals
On February 12, Massachusetts-headquartered Ampersand Capital Partners announced its acquisition of Purna Pharmaceuticals. Purna Pharmaceuticals is an independent Belgian company established in 1986. The company provides contract services for the development and manufacturing of semi-solid, powders and liquid pharmaceutical products that meet GXP standards as well as specific customer-related requirements. Founded in 1988, Ampersand is a middle-market private equity firm with more than $3 billion of assets under management dedicated to investments in the life sciences and healthcare sectors. As part of Ampersand’s broader life sciences portfolio, the investment creates opportunities for... Read More »
Arcline Investment Management Sells Resolution Medical to Resonetics
Arcline Investment Management, a Nashville, Tennessee-based private equity firm, announced that it has entered into a definitive agreement to sell its portfolio company Resolution Medical to Resonetics. Based in Fridley, Minnesota, Resolution Medical is a scaled, end-to-end engineering services and outsourced manufacturing partner focused on complex Class II and III devices for medical technology markets including structural heart, cardiology and vascular, electrophysiology and neuromodulation therapies. With 240 employees, Resolution Medical provides expertise in device design, prototyping, bio-simulation and product design, through to finished device manufacturing. Founded in 1987,... Read More »
Life Sciences R&D M&A Market Overview: Strategic Buyers Amid a Cooling Market
Despite a recent cooling in Life Sciences R&D, there has been a shift among buyers towards more selective, strategic acquisitions that prioritize quality over quantity. The Life Sciences R&D sector, encompassing clinical trial management, contract research organization (CRO) services and contract development and manufacturing organization (CDMO) capabilities, plays a central role in biopharmaceutical innovation. These providers help drug developers overcome steep costs, lengthy timelines and regulatory hurdles to deliver new therapies to patients. With biopharma companies under pressure to accelerate pipelines amid rising chronic disease burdens and aging populations, outsourcing... Read More »
The IMA Group Expands Clinical Research Division With Chicago Acquisition
The IMA Group announced on October 8 the acquisition of Chicago Research Center (CRC), an independent clinical research site based in Chicago, Illinois. Founded in 2005, CRC is known for its expertise in Phase I–IV trials, focused on the central nervous system, sleep disorders, mood and memory disorders, pain and general medicine. The company operates a research sleep lab for dedicated use in insomnia, apnea, narcolepsy, restless leg and shift work sleep disorder clinical trials. The IMA Group provides government workers with medical, psychological and related evaluations, as well as ancillary services, assists payers with case management and occupational health management solutions and... Read More »
